{"id":20290,"date":"2026-08-04T14:37:07","date_gmt":"2026-08-04T09:07:07","guid":{"rendered":"https:\/\/operonstrategist.com\/?p=20290"},"modified":"2026-11-14T14:23:37","modified_gmt":"2026-11-14T08:53:37","slug":"anvisa-medical-device-approval","status":"publish","type":"post","link":"https:\/\/operonstrategist.com\/br-en\/anvisa-medical-device-approval\/","title":{"rendered":"Why ANVISA Medical Device Approvals Fail in Brazil &#038; How to Fix Them"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-post\" data-elementor-id=\"20290\" class=\"elementor elementor-20290\" data-elementor-post-type=\"post\">\n\t\t\t\t<div class=\"elementor-element elementor-element-6cb6d84 e-con-full e-flex e-con e-child\" data-id=\"6cb6d84\" data-element_type=\"container\" data-e-type=\"container\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t\t<div class=\"elementor-element elementor-element-9c5f170 elementor-widget__width-initial elementor-widget elementor-widget-author-box\" data-id=\"9c5f170\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"author-box.default\">\n\t\t\t\t\t\t\t<div class=\"elementor-author-box\">\n\t\t\t\t\t\t\t<div  class=\"elementor-author-box__avatar\">\n\t\t\t\t\t<img decoding=\"async\" src=\"https:\/\/operonstrategist.com\/wp-content\/uploads\/2026\/10\/Vyankatesh_D-300x300.webp\" alt=\"Picture of by Vyankatesh Dhavale\" loading=\"lazy\">\n\t\t\t\t<\/div>\n\t\t\t\n\t\t\t<div class=\"elementor-author-box__text\">\n\t\t\t\t\t\t\t\t\t<div >\n\t\t\t\t\t\t<div class=\"elementor-author-box__name\">\n\t\t\t\t\t\t\tby Vyankatesh Dhavale\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-author-box__bio\">\n\t\t\t\t\t\t<p>Senior Sales Executive | 3 Years of Experience<\/p>\n\t\t\t\t\t<\/div>\n\t\t\t\t\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-6f6ad579 e-flex e-con-boxed e-con e-parent\" data-id=\"6f6ad579\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t<div class=\"elementor-element elementor-element-35c8ffa5 e-con-full e-flex e-con e-child\" data-id=\"35c8ffa5\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-a3e101b elementor-widget elementor-widget-heading\" data-id=\"a3e101b\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">Key Takeaway<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-132c0bcb elementor-widget elementor-widget-text-editor\" data-id=\"132c0bcb\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p>Securing <strong>ANVISA medical device approval in Brazil<\/strong> frequently stalls not due to clinical safety failures, but because of preventable administrative and regulatory misalignments. The primary root causes include incorrect risk classification under <strong>RDC 751\/2022<\/strong>, superficial English-to-Portuguese translations lacking local clinical context, uncertified Brazilian Registration Holder (BRH) representation, missing mandatory <strong>INMETRO certification<\/strong>, and defensive query responses to official <em>Exig\u00eancias<\/em>. Manufacturers can recover stalled applications by performing a strategic gap audit, aligning technical dossiers with ANVISA\u2019s review flow, and engaging localized regulatory expertise.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-f795bb0 e-con-full elementor-hidden-desktop elementor-hidden-tablet e-flex e-con e-child\" data-id=\"f795bb0\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-8cac5a7 elementor-widget elementor-widget-heading\" data-id=\"8cac5a7\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t\t<span class=\"elementor-heading-title elementor-size-default\">Looking for Medical Device Manufacturing Consultant\n<\/span>\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-0b2356d elementor-widget elementor-widget-wpforms\" data-id=\"0b2356d\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"wpforms.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<div class=\"wpforms-container wpforms-container-full wpforms-render-modern\" id=\"wpforms-6203\"><form id=\"wpforms-form-6203\" class=\"wpforms-validate wpforms-form wpforms-ajax-form\" data-formid=\"6203\" method=\"post\" enctype=\"multipart\/form-data\" action=\"\/br-en\/wp-json\/wp\/v2\/posts\/20290\" data-token=\"d10628ecd7eca7968497d3a4c8f4d9ec\" data-token-time=\"1794746296\"><noscript class=\"wpforms-error-noscript\">Please enable JavaScript in your browser to complete this form.<\/noscript><div id=\"wpforms-error-noscript\" style=\"display: none;\">Please enable JavaScript in your browser to complete this form.<\/div><div class=\"wpforms-field-container\"><div id=\"wpforms-6203-field_1-container\" class=\"wpforms-field wpforms-field-name\" data-field-type=\"name\" data-field-id=\"1\"><label class=\"wpforms-field-label wpforms-label-hide\" for=\"wpforms-6203-field_1\" aria-hidden=\"false\">Name <span class=\"wpforms-required-label\" aria-hidden=\"true\">*<\/span><\/label><input type=\"text\" id=\"wpforms-6203-field_1\" class=\"wpforms-field-large wpforms-field-required\" name=\"wpforms[fields][1]\" placeholder=\"Name*\" aria-errormessage=\"wpforms-6203-field_1-error\" required><\/div><div id=\"wpforms-6203-field_2-container\" class=\"wpforms-field wpforms-field-email\" data-field-type=\"email\" data-field-id=\"2\"><label class=\"wpforms-field-label wpforms-label-hide\" for=\"wpforms-6203-field_2\" aria-hidden=\"false\">Email <span class=\"wpforms-required-label\" aria-hidden=\"true\">*<\/span><\/label><input type=\"email\" id=\"wpforms-6203-field_2\" class=\"wpforms-field-large wpforms-field-required\" name=\"wpforms[fields][2]\" placeholder=\"Email*\" spellcheck=\"false\" aria-errormessage=\"wpforms-6203-field_2-error\" required><\/div><div id=\"wpforms-6203-field_3-container\" class=\"wpforms-field wpforms-field-phone\" data-field-type=\"phone\" data-field-id=\"3\"><label class=\"wpforms-field-label wpforms-label-hide\" for=\"wpforms-6203-field_3\" aria-hidden=\"false\">Phone <span class=\"wpforms-required-label\" aria-hidden=\"true\">*<\/span><\/label><input type=\"tel\" id=\"wpforms-6203-field_3\" class=\"wpforms-field-large wpforms-field-required wpforms-smart-phone-field\" data-rule-smart-phone-field=\"true\" name=\"wpforms[fields][3]\" placeholder=\"Phone*\" aria-label=\"Phone\" aria-errormessage=\"wpforms-6203-field_3-error\" required><\/div>\t\t<div id=\"wpforms-6203-field_5-container\"\n\t\t\tclass=\"wpforms-field wpforms-field-text\"\n\t\t\tdata-field-type=\"text\"\n\t\t\tdata-field-id=\"5\"\n\t\t\t>\n\t\t\t<label class=\"wpforms-field-label\" for=\"wpforms-6203-field_5\" >Paragraph Name Phone<\/label>\n\t\t\t<input type=\"text\" id=\"wpforms-6203-field_5\" class=\"wpforms-field-medium\" name=\"wpforms[fields][5]\" >\n\t\t<\/div>\n\t\t<div id=\"wpforms-6203-field_4-container\" class=\"wpforms-field wpforms-field-textarea\" data-field-type=\"textarea\" data-field-id=\"4\"><label class=\"wpforms-field-label wpforms-label-hide\" for=\"wpforms-6203-field_4\" aria-hidden=\"false\">Paragraph Text <span class=\"wpforms-required-label\" aria-hidden=\"true\">*<\/span><\/label><textarea id=\"wpforms-6203-field_4\" class=\"wpforms-field-medium wpforms-field-required\" name=\"wpforms[fields][4]\" placeholder=\"Message\" aria-errormessage=\"wpforms-6203-field_4-error\" required><\/textarea><\/div><script>\n\t\t\t\t( function() {\n\t\t\t\t\tconst style = document.createElement( 'style' );\n\t\t\t\t\tstyle.appendChild( document.createTextNode( '#wpforms-6203-field_5-container { position: absolute !important; overflow: hidden !important; display: inline !important; height: 1px !important; width: 1px !important; z-index: -1000 !important; padding: 0 !important; } #wpforms-6203-field_5-container input { visibility: hidden; } #wpforms-conversational-form-page #wpforms-6203-field_5-container label { counter-increment: none; }' ) );\n\t\t\t\t\tdocument.head.appendChild( style );\n\t\t\t\t\tdocument.currentScript?.remove();\n\t\t\t\t} )();\n\t\t\t<\/script><\/div><!-- .wpforms-field-container --><div class=\"wpforms-recaptcha-container wpforms-is-recaptcha wpforms-is-recaptcha-type-v3\" ><input type=\"hidden\" name=\"wpforms[recaptcha]\" value=\"\"><\/div><div class=\"wpforms-submit-container\" ><input type=\"hidden\" name=\"wpforms[id]\" value=\"6203\"><input type=\"hidden\" name=\"wpforms[time_token]\" value=\"1794746296.c9195fe82c543a291f2cf184aa82a121df8237dbf966df99f5c6822ab2cfea7e\"><input type=\"hidden\" name=\"page_title\" value=\"\"><input type=\"hidden\" name=\"page_url\" value=\"https:\/\/operonstrategist.com\/br-en\/wp-json\/wp\/v2\/posts\/20290\"><input type=\"hidden\" name=\"url_referer\" value=\"\"><button type=\"submit\" name=\"wpforms[submit]\" id=\"wpforms-submit-6203\" class=\"wpforms-submit\" data-alt-text=\"Sending...\" data-submit-text=\"Submit\" aria-live=\"assertive\" value=\"wpforms-submit\">Submit<\/button><img decoding=\"async\" src=\"https:\/\/operonstrategist.com\/wp-content\/plugins\/wpforms\/assets\/images\/submit-spin.svg\" class=\"wpforms-submit-spinner\" style=\"display: none;\" width=\"26\" height=\"26\" alt=\"Loading\"><\/div><\/form><\/div>  <!-- .wpforms-container -->\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-3faa0706 e-flex e-con-boxed e-con e-parent\" data-id=\"3faa0706\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-5f627e71 elementor-widget elementor-widget-heading\" data-id=\"5f627e71\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">Introduction: Understanding ANVISA\u2019s Approval Reality<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-329839e8 elementor-widget elementor-widget-text-editor\" data-id=\"329839e8\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p class=\"\">Getting <strong>ANVISA medical device approval in Brazil<\/strong> can be challenging for domestic and foreign manufacturers alike. Most market access delays happen due to classification errors, documentation oversights, or regulatory misunderstandings. A widespread and costly misconception among international manufacturers is assuming that ANVISA approval mirrors the US FDA 510(k) or European CE Marking process.<\/p><p class=\"\">That single assumption routinely triggers months of administrative deadlock, repetitive technical queries (<em>Exig\u00eancias<\/em>), protocol suspensions, or outright rejection by the <strong>Brazilian Health Surveillance Agency (ANVISA)<\/strong>.<\/p><p class=\"\">ANVISA (<em>Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria<\/em>) operates with distinct legal mandates and evaluative criteria. While international clinical trials and global safety data are respected, Brazil-specific regulatory expectations determine the ultimate outcome of your submission.<\/p><h3 id=\"user-content-the-realities-of-anvisas-evaluation-process\" class=\"\" data-slug-base=\"the-realities-of-anvisas-evaluation-process\"><span style=\"color: #bf2828;\">The Realities of ANVISA\u2019s Evaluation Process:<\/span><\/h3><ul><li><strong>Strict Local Applicability:<\/strong> ANVISA evaluates how the device functions within the Brazilian clinical and healthcare environment, not just its performance in US or European hospitals.<\/li><li><strong>Documentation Architecture Matters:<\/strong> Brazilian technical reviewers adhere to rigid structural guidelines outlined in <span class=\"inline\"><a class=\"text-link\" href=\"https:\/\/operonstrategist.com\/anvisa\/\" data-tooltip-id=\":rl5:\">ANVISA Medical Device Regulations in Brazil<\/a><\/span>. A file formatted according to FDA eSTAR or EU MDR technical files without Brazilian restructuring will face immediate pushback.<\/li><li><strong>Minor Technical Discrepancies Cause Major Delays:<\/strong> Discrepancies between the Instructions for Use (IFU), labeling symbols, and the primary technical dossier can freeze review timelines for 90 to 180 days.<\/li><li><strong>Stalled Files Are Rarely Final Rejections:<\/strong> Over 80% of ANVISA &#8220;failures&#8221; are not statutory denials; they are regulatory impasses caused by procedural non-conformities that can be systematically recovered.<\/li><\/ul><p class=\"\">To establish a sustainable market entry pathway in Latin America&#8217;s largest economy, manufacturers must integrate a proactive <span class=\"inline\"><a class=\"text-link\" href=\"https:\/\/operonstrategist.com\/elevateplus\/quality-management-system-qms\/\" data-tooltip-id=\":rl7:\">Quality Management System (QMS)<\/a><\/span> aligned with Brazilian statutory norms.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-2eae0a70 elementor-widget elementor-widget-heading\" data-id=\"2eae0a70\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">Top 5 Reasons ANVISA Medical Device Approval Fails in Brazil<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-7f0cdd6c elementor-widget elementor-widget-text-editor\" data-id=\"7f0cdd6c\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<div class=\"mermaid-wrapper relative my-4 w-fit max-w-full cursor-pointer rounded-lg focus-visible:outline focus-visible:outline-2 focus-visible:outline-primary\" tabindex=\"0\" role=\"button\" aria-label=\"Open Mermaid diagram preview\"><img decoding=\"async\" class=\"rounded-lg\" src=\"data:image\/svg+xml;base64,<svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 1491.7609999999997 218.70000000000002" width="1491.7609999999997" height="218.70000000000002" style="--bg:#FFFFFF;--fg:#1E293B;--line:#64748B;--muted:#475569;--surface:#F8FAFC;--border:#CBD5E1;background:var(--bg)">
<style>
  @import url('https://fonts.googleapis.com/css2?family=Inter:wght@400;500;600;700&amp;display=swap');
  text { font-family: 'Inter', system-ui, sans-serif; }
  svg {
    /* Derived from --bg and --fg (overridable via --line, --accent, etc.) */
    --_text:          var(--fg);
    --_text-sec:      var(--muted, color-mix(in srgb, var(--fg) 60%, var(--bg)));
    --_text-muted:    var(--muted, color-mix(in srgb, var(--fg) 40%, var(--bg)));
    --_text-faint:    color-mix(in srgb, var(--fg) 25%, var(--bg));
    --_line:          var(--line, color-mix(in srgb, var(--fg) 50%, var(--bg)));
    --_arrow:         var(--accent, color-mix(in srgb, var(--fg) 85%, var(--bg)));
    --_node-fill:     var(--surface, color-mix(in srgb, var(--fg) 3%, var(--bg)));
    --_node-stroke:   var(--border, color-mix(in srgb, var(--fg) 20%, var(--bg)));
    --_group-fill:    var(--bg);
    --_group-hdr:     color-mix(in srgb, var(--fg) 5%, var(--bg));
    --_inner-stroke:  color-mix(in srgb, var(--fg) 12%, var(--bg));
    --_key-badge:     color-mix(in srgb, var(--fg) 10%, var(--bg));
  }
</style>
<defs>
  <marker id="arrowhead" markerWidth="8" markerHeight="5" refX="7" refY="2.5" orient="auto">
    <polygon points="0 0, 8 2.5, 0 5" fill="var(--_arrow)" stroke="var(--_arrow)" stroke-width="0.75" stroke-linejoin="round" />
  </marker>
  <marker id="arrowhead-start" markerWidth="8" markerHeight="5" refX="1" refY="2.5" orient="auto-start-reverse">
    <polygon points="8 0, 0 2.5, 8 5" fill="var(--_arrow)" stroke="var(--_arrow)" stroke-width="0.75" stroke-linejoin="round" />
  </marker>
</defs>
<polyline class="edge" data-from="A" data-to="B" data-style="solid" data-arrow-start="false" data-arrow-end="true" points="748.8444999999998,76.9 748.8444999999998,94.9 148.41299999999995,94.9 148.41299999999995,112.9" fill="none" stroke="var(--_line)" stroke-width="1" marker-end="url(#arrowhead)" />
<polyline class="edge" data-from="A" data-to="C" data-style="solid" data-arrow-start="false" data-arrow-end="true" points="748.8444999999998,76.9 748.8444999999998,94.9 436.95799999999986,94.9 436.95799999999986,112.9" fill="none" stroke="var(--_line)" stroke-width="1" marker-end="url(#arrowhead)" />
<polyline class="edge" data-from="A" data-to="D" data-style="solid" data-arrow-start="false" data-arrow-end="true" points="748.8444999999998,76.9 748.8444999999998,94.9 748.8444999999998,94.9 748.8444999999998,112.9" fill="none" stroke="var(--_line)" stroke-width="1" marker-end="url(#arrowhead)" />
<polyline class="edge" data-from="A" data-to="E" data-style="solid" data-arrow-start="false" data-arrow-end="true" points="748.8444999999998,76.9 748.8444999999998,94.9 1043.3174999999999,94.9 1043.3174999999999,112.9" fill="none" stroke="var(--_line)" stroke-width="1" marker-end="url(#arrowhead)" />
<polyline class="edge" data-from="A" data-to="F" data-style="solid" data-arrow-start="false" data-arrow-end="true" points="748.8444999999998,76.9 748.8444999999998,94.9 1328.8984999999998,94.9 1328.8984999999998,112.9" fill="none" stroke="var(--_line)" stroke-width="1" marker-end="url(#arrowhead)" />
<g class="node" data-id="A" data-label="ANVISA Submission Bottlenecks" data-shape="rectangle">
  <rect x="633.0214999999998" y="40" width="231.64599999999996" height="36.900000000000006" rx="0" ry="0" fill="var(--_node-fill)" stroke="var(--_node-stroke)" stroke-width="0.75" />
  <text x="748.8444999999998" y="58.45" text-anchor="middle" font-size="13" font-weight="500" fill="var(--_text)" dy="4.55">ANVISA Submission Bottlenecks</text>
</g>
<g class="node" data-id="B" data-label="1. Incorrect Risk Classification
(Ignoring RDC 751/2022 Rules)" data-shape="rectangle">
  <rect x="40" y="112.9" width="216.82599999999994" height="53.800000000000004" rx="0" ry="0" fill="var(--_node-fill)" stroke="var(--_node-stroke)" stroke-width="0.75" />
  <text x="148.41299999999995" y="139.8" text-anchor="middle" font-size="13" font-weight="500" fill="var(--_text)"><tspan x="148.41299999999995" dy="-3.9000000000000012">1. Incorrect Risk Classification</tspan><tspan x="148.41299999999995" dy="16.900000000000002">(Ignoring RDC 751/2022 Rules)</tspan></text>
</g>
<g class="node" data-id="C" data-label="2. Superficial Localization
(Direct Translation vs Regulatory Adaptation)" data-shape="rectangle">
  <rect x="284.8259999999999" y="112.9" width="304.2639999999999" height="53.800000000000004" rx="0" ry="0" fill="var(--_node-fill)" stroke="var(--_node-stroke)" stroke-width="0.75" />
  <text x="436.95799999999986" y="139.8" text-anchor="middle" font-size="13" font-weight="500" fill="var(--_text)"><tspan x="436.95799999999986" dy="-3.9000000000000012">2. Superficial Localization</tspan><tspan x="436.95799999999986" dy="16.900000000000002">(Direct Translation vs Regulatory Adaptation)</tspan></text>
</g>
<g class="node" data-id="D" data-label="3. Mismanaged Query Responses
(Defensive or Contradictory Answers)" data-shape="rectangle">
  <rect x="617.0899999999998" y="112.9" width="263.509" height="53.800000000000004" rx="0" ry="0" fill="var(--_node-fill)" stroke="var(--_node-stroke)" stroke-width="0.75" />
  <text x="748.8444999999998" y="139.8" text-anchor="middle" font-size="13" font-weight="500" fill="var(--_text)"><tspan x="748.8444999999998" dy="-3.9000000000000012">3. Mismanaged Query Responses</tspan><tspan x="748.8444999999998" dy="16.900000000000002">(Defensive or Contradictory Answers)</tspan></text>
</g>
<g class="node" data-id="E" data-label="4. Global Equivalence Assumptions
(Relying Solely on FDA / CE Approvals)" data-shape="rectangle">
  <rect x="908.5989999999998" y="112.9" width="269.43699999999995" height="53.800000000000004" rx="0" ry="0" fill="var(--_node-fill)" stroke="var(--_node-stroke)" stroke-width="0.75" />
  <text x="1043.3174999999999" y="139.8" text-anchor="middle" font-size="13" font-weight="500" fill="var(--_text)"><tspan x="1043.3174999999999" dy="-3.9000000000000012">4. Global Equivalence Assumptions</tspan><tspan x="1043.3174999999999" dy="16.900000000000002">(Relying Solely on FDA / CE Approvals)</tspan></text>
</g>
<g class="node" data-id="F" data-label="5. Poor Pre-Submission Planning
(Missing INMETRO / B-GMP Audits)" data-shape="rectangle">
  <rect x="1206.0359999999998" y="112.9" width="245.7249999999999" height="53.800000000000004" rx="0" ry="0" fill="var(--_node-fill)" stroke="var(--_node-stroke)" stroke-width="0.75" />
  <text x="1328.8984999999998" y="139.8" text-anchor="middle" font-size="13" font-weight="500" fill="var(--_text)"><tspan x="1328.8984999999998" dy="-3.9000000000000012">5. Poor Pre-Submission Planning</tspan><tspan x="1328.8984999999998" dy="16.900000000000002">(Missing INMETRO / B-GMP Audits)</tspan></text>
</g>
</svg>\" alt=\"Mermaid diagram\" \/><\/div><h3 id=\"user-content-1-incorrect-device-classification\" class=\"\" data-slug-base=\"1-incorrect-device-classification\"><span style=\"color: #c72424;\">1. Incorrect Device Classification<\/span><\/h3><p class=\"\">Incorrect risk classification remains the leading catalyst for extended regulatory delays and application suspensions in Brazil. Manufacturers frequently extrapolate their US FDA Class II or EU MDR Class IIa classification directly into Brazil, overlooking ANVISA\u2019s specific classification rules codified under <strong>RDC No. 751\/2022<\/strong>.<\/p><h4 id=\"user-content-common-classification-pitfalls\" class=\"\" data-slug-base=\"common-classification-pitfalls\"><b>Common Classification Pitfalls:<\/b><\/h4><ul><li>Assuming FDA Class II automatically equals ANVISA Class II without checking RDC 751\/2022 Rule 1 to 22.<\/li><li>Overlooking Brazil&#8217;s heightened scrutiny on active implantable devices, software algorithms (SaMD), and aesthetic medical devices.<\/li><li>Misclassifying a device as a low-risk Notification (<em>Notifica\u00e7\u00e3o<\/em> \u2013 Class I\/II) when ANVISA mandates a formal Registration (<em>Registro<\/em> \u2013 Class III\/IV).<\/li><\/ul><h4 id=\"user-content-regulatory-impact\" class=\"\" data-slug-base=\"regulatory-impact\"><b>Regulatory Impact:<\/b><\/h4><p class=\"\">When ANVISA discovers an under-classified device, the review protocol is suspended immediately. The applicant is forced to submit a brand-new <em>Registro<\/em> dossier, pay additional health surveillance fees (TFVS), and reset the official review queue.<\/p><blockquote class=\"relative my-2 pl-4 before:absolute before:inset-y-0 before:left-0 before:w-1 before:rounded-full before:bg-border\"><p class=\"\"><strong>The Fix:<\/strong> Classify your medical device strictly through the lens of ANVISA RDC 751\/2022. Verify intended use, contact duration, invasiveness, and energy delivery against Brazilian classification rules before drafting technical documentation.<\/p><\/blockquote><h3 id=\"user-content-2-documentation-that-is-globally-correct-but-locally-wrong\" class=\"\" data-slug-base=\"2-documentation-that-is-globally-correct-but-locally-wrong\"><span style=\"color: #c72424;\">2. Documentation That Is &#8220;Globally Correct&#8221; but &#8220;Locally Wrong&#8221;<\/span><\/h3><p class=\"\">ANVISA accepts international clinical and bench-testing data; however, acceptance is strictly conditional upon localized regulatory formatting. Submitting a direct literal translation of a European or American dossier almost always results in official queries.<\/p><h4 id=\"user-content-common-localization-errors\" class=\"\" data-slug-base=\"common-localization-errors\"><b>Common Localization Errors:<\/b><\/h4><ul><li><strong>Instructions for Use (IFU \/ <em>Instru\u00e7\u00f5es de Uso<\/em>):<\/strong> Translating manuals using automated software without aligning terminology with Brazilian clinical terminology, official metric units, and disposal guidelines.<\/li><li><strong>Missing Mandatory Portuguese Labeling Elements:<\/strong> Failing to include the Brazilian Registration Holder\u2019s (BRH) corporate details, CNPJ number, technical manager (<em>Respons\u00e1vel T\u00e9cnico<\/em>) credentials, and ANVISA registration number placeholders.<\/li><li><strong>Ignoring Local Standards:<\/strong> Neglecting mandatory Brazilian technical norms, such as ABNT NBR standards or compulsory certification frameworks detailed in our guide on <span class=\"inline\"><a class=\"text-link\" href=\"https:\/\/operonstrategist.com\/br-en\/inmetro-certification-medical-devices\/\" data-tooltip-id=\":rl9:\">INMETRO Certification for Medical Devices in Brazil<\/a><\/span>.<\/li><\/ul><blockquote class=\"relative my-2 pl-4 before:absolute before:inset-y-0 before:left-0 before:w-1 before:rounded-full before:bg-border\"><p class=\"\"><strong>The Fix:<\/strong> Treat Brazilian localization as an engineering and regulatory adaptation, not a translation exercise. Every document\u2014from the risk analysis (ISO 14971) to secondary packaging mockups\u2014must comply with Chapter VI of RDC 751\/2022.<\/p><\/blockquote><h3 id=\"user-content-3-misunderstanding-and-mismanaging-anvisas-review-queries-exig\u00eancias\" class=\"\" data-slug-base=\"3-misunderstanding-and-mismanaging-anvisas-review-queries-exig\u00eancias\"><span style=\"color: #c72424;\">3. Misunderstanding and Mismanaging ANVISA&#8217;s Review Queries (<em>Exig\u00eancias<\/em>)<\/span><\/h3><p class=\"\">When ANVISA reviewers identify inconsistencies or missing data, they issue a formal clarification notice termed an <em><strong>Exig\u00eancia T\u00e9cnica<\/strong><\/em>. The legal deadline to respond is typically <strong>30 consecutive days<\/strong> (extendable once for an additional 30 days upon formal request). Panicked or rushed responses frequently transform a manageable query into an outright rejection.<\/p><h4 id=\"user-content-common-query-response-blunders\" class=\"\" data-slug-base=\"common-query-response-blunders\"><b>Common Query Response Blunders:<\/b><\/h4><ul><li><strong>Over-Answering:<\/strong> Providing extraneous test reports, design histories, or validation files that were never requested, which opens new avenues for regulatory questioning.<\/li><li><strong>Defensive Explanations:<\/strong> Debating the reviewer&#8217;s clinical interpretation rather than providing empirical data, risk assessments, or localized justifications.<\/li><li><strong>Creating File Contradictions:<\/strong> Introducing new test versions that contradict earlier statements in the primary technical dossier.<\/li><\/ul><blockquote class=\"relative my-2 pl-4 before:absolute before:inset-y-0 before:left-0 before:w-1 before:rounded-full before:bg-border\"><p class=\"\"><strong>The Fix:<\/strong> Respond like a regulatory authority, not a defensive manufacturer. Structure every response point-by-point, cross-referencing specific articles of ANVISA resolutions, and provide concise, verifiable documentation.<\/p><\/blockquote><h3 id=\"user-content-4-assuming-fda-clearance-or-ce-marking-guarantees-fast-track-approval\" class=\"\" data-slug-base=\"4-assuming-fda-clearance-or-ce-marking-guarantees-fast-track-approval\"><span style=\"color: #c72424;\">4. Assuming FDA Clearance or CE Marking Guarantees Fast-Track Approval<\/span><\/h3><p class=\"\">Relying on foreign approvals to bypass Brazilian regulatory requirements is an expensive miscalculation. While foreign clearances prove technical viability, ANVISA operates as an independent sovereign health agency.<\/p><h4 id=\"user-content-the-regulatory-reality\" class=\"\" data-slug-base=\"the-regulatory-reality\"><b>The Regulatory Reality:<\/b><\/h4><ul><li><strong>No Automatic Reciprocity:<\/strong> ANVISA does not grant automatic market authorization based solely on a 510(k) clearance letter or CE Certificate.<\/li><li><strong>Different Clinical Weight:<\/strong> European clinical evaluations (MEDDEV or MDR CERs) may require supplementary demographic or clinical validation if the indication doesn&#8217;t reflect Brazilian epidemiological profiles.<\/li><li><strong>B-GMP Certification Requirements:<\/strong> For Class III and IV devices, ANVISA mandates Brazilian Good Manufacturing Practice (B-GMP) certification under <strong>RDC 665\/2022<\/strong> or validation via the Medical Device Single Audit Program (MDSAP).<\/li><\/ul><blockquote class=\"relative my-2 pl-4 before:absolute before:inset-y-0 before:left-0 before:w-1 before:rounded-full before:bg-border\"><p class=\"\"><strong>The Fix:<\/strong> Leverage your international test data as supporting technical evidence, but ensure the core dossier maps directly to ANVISA\u2019s unique regulatory structure. If you are also targeting global compliance, coordinate your submissions with specialized <span class=\"inline\"><a class=\"text-link\" href=\"https:\/\/operonstrategist.com\/elevateplus\/us-fda-510k-qmsr-registration\/\" data-tooltip-id=\":rlb:\">US FDA 510(k), QMSR &amp; Registration<\/a><\/span> consulting.<\/p><\/blockquote><h3 id=\"user-content-5-poor-pre-submission-planning-and-inadequate-brh-infrastructure\" class=\"\" data-slug-base=\"5-poor-pre-submission-planning-and-inadequate-brh-infrastructure\"><span style=\"color: #c72424;\">5. Poor Pre-Submission Planning and Inadequate BRH Infrastructure<\/span><\/h3><p class=\"\">Many submission failures originate months before the dossier is submitted. Foreign manufacturers without a physical presence in Brazil must appoint an authorized <strong>Brazilian Registration Holder (BRH)<\/strong> to hold the registration and liaise with ANVISA.<\/p><h4 id=\"user-content-strategic-vulnerabilities\" class=\"\" data-slug-base=\"strategic-vulnerabilities\"><b>Strategic Vulnerabilities:<\/b><\/h4><ul><li>Selecting commercial distributors as the legal BRH, leaving the manufacturer vulnerable to commercial hold-ups if distributor relationships deteriorate.<\/li><li>Filing an application before completing mandatory local testing (e.g., INMETRO electrical safety testing under IEC 60601).<\/li><li>Neglecting establishment licensing (<em>Autoriza\u00e7\u00e3o de Funcionamento de Empresa<\/em> \u2013 AFE) verification for the local warehousing partner.<\/li><\/ul><blockquote class=\"relative my-2 pl-4 before:absolute before:inset-y-0 before:left-0 before:w-1 before:rounded-full before:bg-border\"><p class=\"\"><strong>The Fix:<\/strong> Conduct a comprehensive pre-submission readiness review. Engage an independent third-party BRH or neutral regulatory consulting partner to maintain full commercial control of your product licenses across Brazil.<\/p><\/blockquote>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-749e3c45 elementor-widget elementor-widget-heading\" data-id=\"749e3c45\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">Delay vs. Rejection vs. Formal Query: Know the Difference<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-158c540 elementor-widget elementor-widget-text-editor\" data-id=\"158c540\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p class=\"\">Understanding where your application stands inside ANVISA\u2019s system prevents premature panic and enables targeted corrective action:<\/p><div class=\"group\/md-table relative my-4 md-table-host\" data-width-mode=\"column\"><div class=\"pointer-events-none sticky top-0 z-[5] -mb-8 flex h-8 items-start justify-end px-2\"><div class=\"mt-2 transition-opacity pointer-events-auto can-hover:opacity-0 can-hover:pointer-events-none group-hover\/md-table:opacity-100 group-hover\/md-table:pointer-events-auto group-focus-within\/md-table:opacity-100 group-focus-within\/md-table:pointer-events-auto\">\u00a0<\/div><\/div><div class=\"w-full overflow-x-auto overflow-y-hidden md-table-scroll\"><div class=\"agy-md-table relative w-fit min-w-full rounded-lg overflow-hidden border\" data-md-table=\":rlc:\"><table class=\"md-table-el min-w-full border-separate border-spacing-0\"><thead><tr class=\"\"><th class=\"bg-secondary px-3 py-2 text-start font-medium leading-snug border-t border-b-0 border-s border-e-0 first:border-s-0\">Submission Status<\/th><th class=\"bg-secondary px-3 py-2 text-start font-medium leading-snug border-t border-b-0 border-s border-e-0 first:border-s-0\">ANVISA System Indication<\/th><th class=\"bg-secondary px-3 py-2 text-start font-medium leading-snug border-t border-b-0 border-s border-e-0 first:border-s-0\">Operational Meaning<\/th><th class=\"bg-secondary px-3 py-2 text-start font-medium leading-snug border-t border-b-0 border-s border-e-0 first:border-s-0\">Strategic Corrective Action<\/th><\/tr><\/thead><tbody><tr class=\"\"><td class=\"px-3 py-2 text-start leading-snug border-t border-b-0 border-s border-e-0 first:border-s-0\"><strong>Prolonged Silence<\/strong><\/td><td class=\"px-3 py-2 text-start leading-snug border-t border-b-0 border-s border-e-0 first:border-s-0\"><em>Aguardando An\u00e1lise<\/em> (Awaiting Analysis)<\/td><td class=\"px-3 py-2 text-start leading-snug border-t border-b-0 border-s border-e-0 first:border-s-0\">Normal procedural queue delay; review has not commenced.<\/td><td class=\"px-3 py-2 text-start leading-snug border-t border-b-0 border-s border-e-0 first:border-s-0\">Monitor official ANVISA processing queues; do not submit unsolicited document updates.<\/td><\/tr><tr class=\"\"><td class=\"px-3 py-2 text-start leading-snug border-t border-b-0 border-s border-e-0 first:border-s-0\"><strong>Document Query<\/strong><\/td><td class=\"px-3 py-2 text-start leading-snug border-t border-b-0 border-s border-e-0 first:border-s-0\"><em>Exig\u00eancia T\u00e9cnica Formulada<\/em><\/td><td class=\"px-3 py-2 text-start leading-snug border-t border-b-0 border-s border-e-0 first:border-s-0\">Non-fatal technical gap or clarification request identified.<\/td><td class=\"px-3 py-2 text-start leading-snug border-t border-b-0 border-s border-e-0 first:border-s-0\">Request an immediate 30-day extension if needed; prepare an exact, localized technical response.<\/td><\/tr><tr class=\"\"><td class=\"px-3 py-2 text-start leading-snug border-t border-b-0 border-s border-e-0 first:border-s-0\"><strong>Classification Conflict<\/strong><\/td><td class=\"px-3 py-2 text-start leading-snug border-t border-b-0 border-s border-e-0 first:border-s-0\"><em>Exig\u00eancia de Reenquadramento<\/em><\/td><td class=\"px-3 py-2 text-start leading-snug border-t border-b-0 border-s border-e-0 first:border-s-0\">ANVISA disagrees with device risk tier or grouping strategy.<\/td><td class=\"px-3 py-2 text-start leading-snug border-t border-b-0 border-s border-e-0 first:border-s-0\">Review RDC 751\/2022 rules; justify current grouping or transition to formal <em>Registro<\/em> pathway.<\/td><\/tr><tr class=\"\"><td class=\"px-3 py-2 text-start leading-snug border-t border-b-0 border-s border-e-0 first:border-s-0\"><strong>Application Archival<\/strong><\/td><td class=\"px-3 py-2 text-start leading-snug border-t border-b-0 border-s border-e-0 first:border-s-0\"><em>Processo Arquivado \/ Cancelado<\/em><\/td><td class=\"px-3 py-2 text-start leading-snug border-t border-b-0 border-s border-e-0 first:border-s-0\">Statutory response deadline missed or <em>Exig\u00eancia<\/em> unsatisfied.<\/td><td class=\"px-3 py-2 text-start leading-snug border-t border-b-0 border-s border-e-0 first:border-s-0\">File an administrative appeal (<em>Recurso Administrativo<\/em>) within 15 business days with legal backing.<\/td><\/tr><tr class=\"\"><td class=\"px-3 py-2 text-start leading-snug border-t border-b-0 border-s border-e-0 first:border-s-0\"><strong>Definitive Rejection<\/strong><\/td><td class=\"px-3 py-2 text-start leading-snug border-t border-b-0 border-s border-e-0 first:border-s-0\"><em>Indeferimento Publicado no DOU<\/em><\/td><td class=\"px-3 py-2 text-start leading-snug border-t border-b-0 border-s border-e-0 first:border-s-0\">Unresolvable safety, efficacy, or major regulatory non-compliance.<\/td><td class=\"px-3 py-2 text-start leading-snug border-t border-b-0 border-s border-e-0 first:border-s-0\">Perform root-cause gap analysis; remediate core technical data prior to complete re-filing.<\/td><\/tr><\/tbody><\/table><\/div><\/div><\/div>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-2837d037 elementor-widget elementor-widget-heading\" data-id=\"2837d037\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">Step-by-Step Recovery: How to Fix ANVISA Approval Problems Quickly<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-3b49c072 elementor-widget elementor-widget-text-editor\" data-id=\"3b49c072\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p class=\"\">If your medical device application is stalled, flagged with an <em>Exig\u00eancia<\/em>, or facing administrative deadlock, execute this four-step recovery protocol:<\/p><h3 id=\"user-content-anvisa-approval-recovery-workflow\" class=\"\" data-slug-base=\"anvisa-approval-recovery-workflow\"><span style=\"color: #c72020;\">ANVISA Approval Recovery Workflow<\/span><\/h3><div class=\"mermaid-wrapper relative my-4 w-fit max-w-full cursor-pointer rounded-lg focus-visible:outline focus-visible:outline-2 focus-visible:outline-primary\" tabindex=\"0\" role=\"button\" aria-label=\"Open Mermaid diagram preview\"><img decoding=\"async\" class=\"rounded-lg\" src=\"data:image\/svg+xml;base64,<svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 511.7159999999998 524.1" width="511.7159999999998" height="524.1" style="--bg:#FFFFFF;--fg:#1E293B;--line:#64748B;--muted:#475569;--surface:#F8FAFC;--border:#CBD5E1;background:var(--bg)">
<style>
  @import url('https://fonts.googleapis.com/css2?family=Inter:wght@400;500;600;700&amp;display=swap');
  text { font-family: 'Inter', system-ui, sans-serif; }
  svg {
    /* Derived from --bg and --fg (overridable via --line, --accent, etc.) */
    --_text:          var(--fg);
    --_text-sec:      var(--muted, color-mix(in srgb, var(--fg) 60%, var(--bg)));
    --_text-muted:    var(--muted, color-mix(in srgb, var(--fg) 40%, var(--bg)));
    --_text-faint:    color-mix(in srgb, var(--fg) 25%, var(--bg));
    --_line:          var(--line, color-mix(in srgb, var(--fg) 50%, var(--bg)));
    --_arrow:         var(--accent, color-mix(in srgb, var(--fg) 85%, var(--bg)));
    --_node-fill:     var(--surface, color-mix(in srgb, var(--fg) 3%, var(--bg)));
    --_node-stroke:   var(--border, color-mix(in srgb, var(--fg) 20%, var(--bg)));
    --_group-fill:    var(--bg);
    --_group-hdr:     color-mix(in srgb, var(--fg) 5%, var(--bg));
    --_inner-stroke:  color-mix(in srgb, var(--fg) 12%, var(--bg));
    --_key-badge:     color-mix(in srgb, var(--fg) 10%, var(--bg));
  }
</style>
<defs>
  <marker id="arrowhead" markerWidth="8" markerHeight="5" refX="7" refY="2.5" orient="auto">
    <polygon points="0 0, 8 2.5, 0 5" fill="var(--_arrow)" stroke="var(--_arrow)" stroke-width="0.75" stroke-linejoin="round" />
  </marker>
  <marker id="arrowhead-start" markerWidth="8" markerHeight="5" refX="1" refY="2.5" orient="auto-start-reverse">
    <polygon points="8 0, 0 2.5, 8 5" fill="var(--_arrow)" stroke="var(--_arrow)" stroke-width="0.75" stroke-linejoin="round" />
  </marker>
</defs>
<polyline class="edge" data-from="Step1" data-to="Step2" data-style="solid" data-arrow-start="false" data-arrow-end="true" points="255.8579999999999,93.80000000000001 255.8579999999999,141.8" fill="none" stroke="var(--_line)" stroke-width="1" marker-end="url(#arrowhead)" />
<polyline class="edge" data-from="Step2" data-to="Step3" data-style="solid" data-arrow-start="false" data-arrow-end="true" points="255.8579999999999,195.60000000000002 255.8579999999999,243.60000000000002" fill="none" stroke="var(--_line)" stroke-width="1" marker-end="url(#arrowhead)" />
<polyline class="edge" data-from="Step3" data-to="Step4" data-style="solid" data-arrow-start="false" data-arrow-end="true" points="255.8579999999999,297.40000000000003 255.8579999999999,345.40000000000003" fill="none" stroke="var(--_line)" stroke-width="1" marker-end="url(#arrowhead)" />
<polyline class="edge" data-from="Step4" data-to="Approved" data-style="solid" data-arrow-start="false" data-arrow-end="true" points="255.8579999999999,399.20000000000005 255.8579999999999,447.20000000000005" fill="none" stroke="var(--_line)" stroke-width="1" marker-end="url(#arrowhead)" />
<g class="node" data-id="Step1" data-label="Step 1: Diagnostic Gap Audit
(Isolate Classification vs Documentation vs Clinical Deficit)" data-shape="rectangle">
  <rect x="68.89899999999997" y="40" width="373.91799999999984" height="53.800000000000004" rx="0" ry="0" fill="var(--_node-fill)" stroke="var(--_node-stroke)" stroke-width="0.75" />
  <text x="255.8579999999999" y="66.9" text-anchor="middle" font-size="13" font-weight="500" fill="var(--_text)"><tspan x="255.8579999999999" dy="-3.9000000000000012">Step 1: Diagnostic Gap Audit</tspan><tspan x="255.8579999999999" dy="16.900000000000002">(Isolate Classification vs Documentation vs Clinical Deficit)</tspan></text>
</g>
<g class="node" data-id="Step2" data-label="Step 2: Structural Dossier Realignment
(Restructure Technical File to Match ANVISA Review Logic)" data-shape="rectangle">
  <rect x="61.48899999999992" y="141.8" width="388.73799999999994" height="53.800000000000004" rx="0" ry="0" fill="var(--_node-fill)" stroke="var(--_node-stroke)" stroke-width="0.75" />
  <text x="255.8579999999999" y="168.70000000000002" text-anchor="middle" font-size="13" font-weight="500" fill="var(--_text)"><tspan x="255.8579999999999" dy="-3.9000000000000012">Step 2: Structural Dossier Realignment</tspan><tspan x="255.8579999999999" dy="16.900000000000002">(Restructure Technical File to Match ANVISA Review Logic)</tspan></text>
</g>
<g class="node" data-id="Step3" data-label="Step 3: Strategic Query Response Formulation
(Draft Factual, Regulator-Aligned Evidence within Statutory Window)" data-shape="rectangle">
  <rect x="40" y="243.60000000000002" width="431.7159999999998" height="53.800000000000004" rx="0" ry="0" fill="var(--_node-fill)" stroke="var(--_node-stroke)" stroke-width="0.75" />
  <text x="255.8579999999999" y="270.5" text-anchor="middle" font-size="13" font-weight="500" fill="var(--_text)"><tspan x="255.8579999999999" dy="-3.9000000000000012">Step 3: Strategic Query Response Formulation</tspan><tspan x="255.8579999999999" dy="16.900000000000002">(Draft Factual, Regulator-Aligned Evidence within Statutory Window)</tspan></text>
</g>
<g class="node" data-id="Step4" data-label="Step 4: Engage Localized Regulatory Expertise
(Direct Dialogue with ANVISA Reviewers &amp; BRH Oversight)" data-shape="rectangle">
  <rect x="67.04649999999992" y="345.40000000000003" width="377.62299999999993" height="53.800000000000004" rx="0" ry="0" fill="var(--_node-fill)" stroke="var(--_node-stroke)" stroke-width="0.75" />
  <text x="255.8579999999999" y="372.3" text-anchor="middle" font-size="13" font-weight="500" fill="var(--_text)"><tspan x="255.8579999999999" dy="-3.9000000000000012">Step 4: Engage Localized Regulatory Expertise</tspan><tspan x="255.8579999999999" dy="16.900000000000002">(Direct Dialogue with ANVISA Reviewers &amp; BRH Oversight)</tspan></text>
</g>
<g class="node" data-id="Approved" data-label="Official Gazette (DOU) Approval &amp; Market Access" data-shape="rectangle">
  <rect x="94.46349999999993" y="447.20000000000005" width="322.78899999999993" height="36.900000000000006" rx="0" ry="0" fill="var(--_node-fill)" stroke="var(--_node-stroke)" stroke-width="0.75" />
  <text x="255.8579999999999" y="465.65000000000003" text-anchor="middle" font-size="13" font-weight="500" fill="var(--_text)" dy="4.55">Official Gazette (DOU) Approval &amp; Market Access</text>
</g>
</svg>\" alt=\"Mermaid diagram\" \/><\/div><h3 id=\"user-content-step-1-identify-the-true-regulatory-bottleneck\" class=\"\" data-slug-base=\"step-1-identify-the-true-regulatory-bottleneck\"><span style=\"color: #c72020;\">Step 1: Identify the True Regulatory Bottleneck<\/span><\/h3><p class=\"\">Avoid making arbitrary changes to your submission. Determine whether ANVISA&#8217;s concern stems from:<\/p><ul><li>Risk classification under RDC 751\/2022<\/li><li>Missing local test reports (biocompatibility, electrical safety, or sterilization validation)<\/li><li>Non-compliant Portuguese labeling or clinical claims in the IFU<\/li><li>Quality system non-compliance under B-GMP (RDC 665\/2022)<\/li><\/ul><h3 id=\"user-content-step-2-realign-your-technical-file-with-anvisa-review-logic\" class=\"\" data-slug-base=\"step-2-realign-your-technical-file-with-anvisa-review-logic\"><span style=\"color: #c72020;\">Step 2: Realign Your Technical File with ANVISA Review Logic<\/span><\/h3><p class=\"\">Brazilian reviewers evaluate files sequentially. Restructure your technical dossier (<em>Relat\u00f3rio T\u00e9cnico<\/em>) so that clinical justifications, bench testing, and risk management matrices directly support your product claims according to <span class=\"inline\"><a class=\"text-link\" href=\"https:\/\/operonstrategist.com\/br-en\/medical-device-registration-in-brazil\/\" data-tooltip-id=\":rlk:\">Medical Device Registration in Brazil<\/a><\/span> benchmarks.<\/p><h3 id=\"user-content-step-3-respond-to-queries-like-a-regulator\" class=\"\" data-slug-base=\"step-3-respond-to-queries-like-a-regulator\"><span style=\"color: #c72020;\">Step 3: Respond to Queries Like a Regulator<\/span><\/h3><p class=\"\">When replying to an <em>Exig\u00eancia T\u00e9cnica<\/em>:<\/p><ul><li>Provide clear, concise answers without emotional justification.<\/li><li>Cite specific ANVISA resolutions, Brazilian Pharmacopoeia references, or ABNT standards.<\/li><li>Ensure all supporting attachments (e.g., test reports) are translated by a certified translator (<em>Tradu\u00e7\u00e3o Juramentada<\/em>) if requested.<\/li><\/ul><h3 id=\"user-content-step-4-leverage-brazil-specific-regulatory-consulting\" class=\"\" data-slug-base=\"step-4-leverage-brazil-specific-regulatory-consulting\"><span style=\"color: #c72020;\">Step 4: Leverage Brazil-Specific Regulatory Consulting<\/span><\/h3><p class=\"\">Generic international consulting firms unfamiliar with Brazilian administrative case law frequently falter during technical query negotiations. Retaining local regulatory specialists who understand ANVISA\u2019s internal review culture eliminates delays and restores reviewer confidence.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-66224c4c e-con-full e-flex e-con e-child\" data-id=\"66224c4c\" data-element_type=\"container\" data-e-type=\"container\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t<div class=\"elementor-element elementor-element-4eff21f5 e-con-full e-flex e-con e-child\" data-id=\"4eff21f5\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-53bb99f3 elementor-widget elementor-widget-heading\" data-id=\"53bb99f3\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t\t<span class=\"elementor-heading-title elementor-size-default\">Facing an ANVISA Exig\u00eancia or Stalled Medical Device Submission?<\/span>\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-4fcbfaba elementor-widget elementor-widget-text-editor\" data-id=\"4fcbfaba\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p>Unresolved ANVISA queries can lead to application archival within 30 days. Protect your investment by partnering with Operon Strategist\u2019s regulatory specialists to formulate audit-proof, regulator-aligned query responses.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-2bb85e0f e-con-full e-flex e-con e-child\" data-id=\"2bb85e0f\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-6459a585 elementor-align-right elementor-mobile-align-left elementor-widget elementor-widget-button\" data-id=\"6459a585\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"button.default\">\n\t\t\t\t\t\t\t\t\t\t<a class=\"elementor-button elementor-button-link elementor-size-sm\" href=\"https:\/\/operonstrategist.com\/contact-us\/\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t\t\t\t<span class=\"elementor-button-text\">Contact Us<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-37f99e09 e-flex e-con-boxed e-con e-parent\" data-id=\"37f99e09\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-e796b6b elementor-widget elementor-widget-heading\" data-id=\"e796b6b\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">What We Commonly See in Real ANVISA Submissions<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-2455bfa7 elementor-widget elementor-widget-text-editor\" data-id=\"2455bfa7\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p class=\"\">Based on extensive hands-on regulatory experience across international submissions in Brazil, clear patterns emerge regarding why medical device approvals fail:<\/p><h3 id=\"user-content-real-world-anvisa-submission-insights\" class=\"\" data-slug-base=\"real-world-anvisa-submission-insights\"><span style=\"color: #c72020;\">Real-World ANVISA Submission Insights<\/span><\/h3><div class=\"group\/md-table relative my-4 md-table-host\" data-width-mode=\"column\"><div class=\"pointer-events-none sticky top-0 z-[5] -mb-8 flex h-8 items-start justify-end px-2\"><div class=\"mt-2 transition-opacity pointer-events-auto can-hover:opacity-0 can-hover:pointer-events-none group-hover\/md-table:opacity-100 group-hover\/md-table:pointer-events-auto group-focus-within\/md-table:opacity-100 group-focus-within\/md-table:pointer-events-auto\">\u00a0<\/div><\/div><div class=\"w-full overflow-x-auto overflow-y-hidden md-table-scroll\"><div class=\"agy-md-table relative w-fit min-w-full rounded-lg overflow-hidden border\" data-md-table=\":rln:\"><table class=\"md-table-el min-w-full border-separate border-spacing-0\"><thead><tr class=\"\"><th class=\"bg-secondary px-3 py-2 text-start font-medium leading-snug border-t border-b-0 border-s border-e-0 first:border-s-0\">Regulatory Focus Area<\/th><th class=\"bg-secondary px-3 py-2 text-start font-medium leading-snug border-t border-b-0 border-s border-e-0 first:border-s-0\">Common Industry Assumption<\/th><th class=\"bg-secondary px-3 py-2 text-start font-medium leading-snug border-t border-b-0 border-s border-e-0 first:border-s-0\">ANVISA Reality &amp; Enforcement<\/th><th class=\"bg-secondary px-3 py-2 text-start font-medium leading-snug border-t border-b-0 border-s border-e-0 first:border-s-0\">Risk Level<\/th><\/tr><\/thead><tbody><tr class=\"\"><td class=\"px-3 py-2 text-start leading-snug border-t border-b-0 border-s border-e-0 first:border-s-0\"><strong>Risk Classification<\/strong><\/td><td class=\"px-3 py-2 text-start leading-snug border-t border-b-0 border-s border-e-0 first:border-s-0\">Global Class II = Brazil Class II<\/td><td class=\"px-3 py-2 text-start leading-snug border-t border-b-0 border-s border-e-0 first:border-s-0\">RDC 751\/2022 reclassifies several software, dental, and aesthetic devices into Class III\/IV.<\/td><td class=\"px-3 py-2 text-start leading-snug border-t border-b-0 border-s border-e-0 first:border-s-0\"><strong>High<\/strong><\/td><\/tr><tr class=\"\"><td class=\"px-3 py-2 text-start leading-snug border-t border-b-0 border-s border-e-0 first:border-s-0\"><strong>Technical Dossier Format<\/strong><\/td><td class=\"px-3 py-2 text-start leading-snug border-t border-b-0 border-s border-e-0 first:border-s-0\">FDA 510(k) or EU STED format is universally accepted<\/td><td class=\"px-3 py-2 text-start leading-snug border-t border-b-0 border-s border-e-0 first:border-s-0\">ANVISA requires specific dossier chapter structures, legal attestations, and BRH declarations.<\/td><td class=\"px-3 py-2 text-start leading-snug border-t border-b-0 border-s border-e-0 first:border-s-0\"><strong>Medium<\/strong><\/td><\/tr><tr class=\"\"><td class=\"px-3 py-2 text-start leading-snug border-t border-b-0 border-s border-e-0 first:border-s-0\"><strong>Labeling &amp; Instructions<\/strong><\/td><td class=\"px-3 py-2 text-start leading-snug border-t border-b-0 border-s border-e-0 first:border-s-0\">Standard English packaging with translated paper inserts<\/td><td class=\"px-3 py-2 text-start leading-snug border-t border-b-0 border-s border-e-0 first:border-s-0\">Outer boxes, primary blisters, and IFUs must carry mandatory Portuguese regulatory data.<\/td><td class=\"px-3 py-2 text-start leading-snug border-t border-b-0 border-s border-e-0 first:border-s-0\"><strong>High<\/strong><\/td><\/tr><tr class=\"\"><td class=\"px-3 py-2 text-start leading-snug border-t border-b-0 border-s border-e-0 first:border-s-0\"><strong>Good Manufacturing Practice<\/strong><\/td><td class=\"px-3 py-2 text-start leading-snug border-t border-b-0 border-s border-e-0 first:border-s-0\">ISO 13485 certificate satisfies all factory inspection rules<\/td><td class=\"px-3 py-2 text-start leading-snug border-t border-b-0 border-s border-e-0 first:border-s-0\">Class III &amp; IV devices require formal B-GMP certification via ANVISA inspection or valid MDSAP audit.<\/td><td class=\"px-3 py-2 text-start leading-snug border-t border-b-0 border-s border-e-0 first:border-s-0\"><strong>Critical<\/strong><\/td><\/tr><tr class=\"\"><td class=\"px-3 py-2 text-start leading-snug border-t border-b-0 border-s border-e-0 first:border-s-0\"><strong>Sterilization Validation<\/strong><\/td><td class=\"px-3 py-2 text-start leading-snug border-t border-b-0 border-s border-e-0 first:border-s-0\">Historical supplier validation reports are sufficient<\/td><td class=\"px-3 py-2 text-start leading-snug border-t border-b-0 border-s border-e-0 first:border-s-0\">Must comply with ISO 11135 \/ ISO 11137 with validated Sterility Assurance Levels (<span class=\"katex\"><span class=\"katex-mathml\">10\u2212610^{-6}<\/span><span class=\"katex-html\" aria-hidden=\"true\"><span class=\"katex-base\"><span class=\"mord\">1<\/span><span class=\"mord\">0<span class=\"msupsub\"><span class=\"vlist-t\"><span class=\"vlist-r\"><span class=\"vlist\"><span class=\"\"><span class=\"katex-sizing reset-size6 size3 mtight\"><span class=\"mord mtight\">\u22126<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span>).<\/td><td class=\"px-3 py-2 text-start leading-snug border-t border-b-0 border-s border-e-0 first:border-s-0\"><strong>Medium<\/strong><\/td><\/tr><\/tbody><\/table><\/div><\/div><\/div><p class=\"\">Our field observations indicate that <strong>over 60% of ANVISA technical queries relate entirely to documentation format and labeling discrepancies<\/strong>, rather than inherent device safety issues. Foreign manufacturers face an average review timeline increase of 6 to 9 months when attempting submissions without localized strategic support.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-79005b8b e-con-full e-flex e-con e-child\" data-id=\"79005b8b\" data-element_type=\"container\" data-e-type=\"container\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t<div class=\"elementor-element elementor-element-62b7c8f0 e-con-full e-flex e-con e-child\" data-id=\"62b7c8f0\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-171e848a elementor-widget elementor-widget-heading\" data-id=\"171e848a\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t\t<span class=\"elementor-heading-title elementor-size-default\">Fast-Track Your Brazil Market Entry with Turnkey ANVISA Support<\/span>\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-302dd15d elementor-widget elementor-widget-text-editor\" data-id=\"302dd15d\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p>Don\u2019t allow preventable documentation mistakes to delay your commercial launch in Latin America. Operon Strategist provides end-to-end dossier compilation, BRH coordination, and B-GMP compliance.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-262d4921 e-con-full e-flex e-con e-child\" data-id=\"262d4921\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-1d873ff6 elementor-align-right elementor-mobile-align-left elementor-widget elementor-widget-button\" data-id=\"1d873ff6\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"button.default\">\n\t\t\t\t\t\t\t\t\t\t<a class=\"elementor-button elementor-button-link elementor-size-sm\" href=\"https:\/\/operonstrategist.com\/contact-us\/\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t\t\t\t<span class=\"elementor-button-text\">Contact Us<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-d972223 elementor-widget elementor-widget-heading\" data-id=\"d972223\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">When to Involve an ANVISA Medical Device Approval Consultant<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-22d1a5fc elementor-widget elementor-widget-text-editor\" data-id=\"22d1a5fc\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p class=\"\">Navigating Brazilian regulatory hurdles independently often leads to avoidable re-work and wasted capital. You should immediately engage a specialized ANVISA regulatory consultant if:<\/p><ul><li><strong>Your Submission Has Been Pending for Over 6 Months:<\/strong> A protracted review without progress often indicates an unaddressed formal query or system stall.<\/li><li><strong>ANVISA Has Issued a High-Impact Exig\u00eancia:<\/strong> Complex queries regarding clinical data, software architecture, or biocompatibility require precise, regulator-level evidence.<\/li><li><strong>You Are Registering a Class III or Class IV Medical Device:<\/strong> High-risk devices require mandatory B-GMP audit clearances, clinical evaluation alignment, and comprehensive risk dossiers.<\/li><li><strong>You Are Planning Turnkey Production or Plant Setup in Brazil:<\/strong> If you are manufacturing locally, as outlined in our blueprint for a <span class=\"inline\"><a class=\"text-link\" href=\"https:\/\/operonstrategist.com\/br-en\/disposable-syringe-manufacturing-plant\/\" data-tooltip-id=\":rm1:\">Disposable Syringe Manufacturing Plant in Brazil<\/a><\/span>, manufacturing plant compliance must integrate both municipal sanitary permits and federal ANVISA licensing.<\/li><\/ul>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-355d8f32 elementor-widget elementor-widget-heading\" data-id=\"355d8f32\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">How Operon Strategist Resolves ANVISA Approval Bottlenecks<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-3c5e7785 elementor-widget elementor-widget-text-editor\" data-id=\"3c5e7785\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p class=\"\">At <span class=\"inline\"><a class=\"text-link\" href=\"https:\/\/operonstrategist.com\/br-en\/\" data-tooltip-id=\":rm3:\">Operon Strategist<\/a><\/span>, we specialize in helping medical device and IVD manufacturers successfully navigate ANVISA approval pathways without delays. Our Brazil-focused regulatory practice provides comprehensive technical, quality, and administrative solutions tailored to international standards.<\/p><h3 id=\"user-content-our-core-capabilities-for-the-brazilian-market\" class=\"\" data-slug-base=\"our-core-capabilities-for-the-brazilian-market\"><span style=\"color: #bf3939;\">Our Core Capabilities for the Brazilian Market:<\/span><\/h3><ul><li><strong>Pre-Submission Gap Audits &amp; Risk Classification:<\/strong> Rigorous technical evaluation of your product against ANVISA RDC No. 751\/2022 to confirm classification, submission pathways (<em>Notifica\u00e7\u00e3o<\/em> vs. <em>Registro<\/em>), and testing prerequisites.<\/li><li><strong>ANVISA Dossier Compilation &amp; Localization:<\/strong> End-to-end technical file compilation conforming to Brazilian regulatory architecture, including localized Portuguese IFUs, compliant packaging mockups, and clinical evaluation adaptation via our <span class=\"inline\"><a class=\"text-link\" href=\"https:\/\/operonstrategist.com\/br-en\/elevateplus\/anvisa-medical-device-registration\/\" data-tooltip-id=\":rm5:\">Medical Device Registration in Brazil<\/a><\/span> services.<\/li><li><strong>Strategic Exig\u00eancia Management &amp; Query Resolution:<\/strong> Rapid drafting and submission of defensible, regulator-aligned responses to official ANVISA queries within statutory deadlines, minimizing review cycles.<\/li><li><strong>B-GMP &amp; Quality Management System Compliance:<\/strong> Alignment of your manufacturing operations with ANVISA RDC 665\/2022 and MDSAP requirements, integrated with our <span class=\"inline\"><a class=\"text-link\" href=\"https:\/\/operonstrategist.com\/br-en\/elevateplus\/quality-management-system-qms\/\" data-tooltip-id=\":rm7:\">ISO 13485 Certification Support<\/a><\/span>.<\/li><li><strong>INMETRO Certification Management:<\/strong> Coordinating product safety, EMC, and performance testing with accredited Brazilian laboratories to secure mandatory INMETRO conformity certificates.<\/li><li><strong>Turnkey Facility Setup &amp; Cleanroom Engineering:<\/strong> For companies manufacturing inside Brazil, we provide end-to-end support from <span class=\"inline\"><a class=\"text-link\" href=\"https:\/\/operonstrategist.com\/buildnext\/plant-layout-detail-engineering\/\" data-tooltip-id=\":rm9:\">Plant Layout Detail Engineering<\/a><\/span> to sanitary operating permits (AFE).<\/li><li><strong>Multi-Market Access Synchronization:<\/strong> Synchronizing your Brazilian approvals with international market expansions through <span class=\"inline\"><a class=\"text-link\" href=\"https:\/\/operonstrategist.com\/br-en\/elevateplus\/ce-marking-eu-mdr-ivdr\/\" data-tooltip-id=\":rmb:\">CE Marking Consulting for Export to EU<\/a><\/span>, <span class=\"inline\"><a class=\"text-link\" href=\"https:\/\/operonstrategist.com\/br-en\/elevateplus\/us-fda-510k-qmsr-registration\/\" data-tooltip-id=\":rmd:\">US FDA 510(k) Consulting<\/a><\/span>, and <span class=\"inline\"><a class=\"text-link\" href=\"https:\/\/operonstrategist.com\/elevateplus\/cdsco-india\/\" data-tooltip-id=\":rmf:\">CDSCO India Registration<\/a><\/span>.<\/li><\/ul>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-94e154e e-con-full e-flex e-con e-child\" data-id=\"94e154e\" data-element_type=\"container\" data-e-type=\"container\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t\t<div class=\"elementor-element elementor-element-2dbc7a9 elementor-widget elementor-widget-author-box\" data-id=\"2dbc7a9\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"author-box.default\">\n\t\t\t\t\t\t\t<div class=\"elementor-author-box\">\n\t\t\t\t\t\t\t<div  class=\"elementor-author-box__avatar\">\n\t\t\t\t\t<img decoding=\"async\" src=\"https:\/\/operonstrategist.com\/wp-content\/uploads\/2026\/10\/Vyankatesh_D-300x300.webp\" alt=\"Picture of Vyankatesh Dhavale\" loading=\"lazy\">\n\t\t\t\t<\/div>\n\t\t\t\n\t\t\t<div class=\"elementor-author-box__text\">\n\t\t\t\t\t\t\t\t\t<div >\n\t\t\t\t\t\t<span class=\"elementor-author-box__name\">\n\t\t\t\t\t\t\tVyankatesh Dhavale\t\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/div>\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-author-box__bio\">\n\t\t\t\t\t\t<p>Senior Sales Executive | 3 Years of Experience<br \/>\n He brings experience in domestic and international business development, strategic client relationship management, and sales of medical device regulatory consulting and turnkey project services. His expertise includes supporting market entry and regulatory service requirements related to CDSCO registration, EU MDR CE marking, US FDA regulations, and ISO 13485 quality management systems.<\/p>\n\t\t\t\t\t<\/div>\n\t\t\t\t\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-6e4cedf elementor-widget elementor-widget-elementskit-social-media\" data-id=\"6e4cedf\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"elementskit-social-media.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<div class=\"ekit-wid-con\" >\t\t\t <ul class=\"ekit_social_media\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<li class=\"elementor-repeater-item-c3f8dd2\">\n\t\t\t\t\t    <a href=\"https:\/\/www.linkedin.com\/in\/vyankatesh-dhavale\/\" aria-label=\"LinkedIn\" class=\"linkedin\" target=\"_blank\" rel=\"noopener\">\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t<svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fab-linkedin\" viewBox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M416 32H31.9C14.3 32 0 46.5 0 64.3v383.4C0 465.5 14.3 480 31.9 480H416c17.6 0 32-14.5 32-32.3V64.3c0-17.8-14.4-32.3-32-32.3zM135.4 416H69V202.2h66.5V416zm-33.2-243c-21.3 0-38.5-17.3-38.5-38.5S80.9 96 102.2 96c21.2 0 38.5 17.3 38.5 38.5 0 21.3-17.2 38.5-38.5 38.5zm282.1 243h-66.4V312c0-24.8-.5-56.7-34.5-56.7-34.6 0-39.9 27-39.9 54.9V416h-66.4V202.2h63.7v29.2h.9c8.9-16.8 30.6-34.5 62.9-34.5 67.2 0 79.7 44.3 79.7 101.9V416z\"><\/path><\/svg>\n                                                                                                            <\/a>\n                    <\/li>\n                    \t\t\t\t\t\t\t<\/ul>\n\t\t<\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-6e46560 e-flex e-con-boxed e-con e-parent\" data-id=\"6e46560\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-e3d8a25 elementor-widget elementor-widget-heading\" data-id=\"e3d8a25\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">FAQ's<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-606ad54 elementor-widget elementor-widget-n-accordion\" data-id=\"606ad54\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;default_state&quot;:&quot;all_collapsed&quot;,&quot;max_items_expended&quot;:&quot;one&quot;,&quot;n_accordion_animation_duration&quot;:{&quot;unit&quot;:&quot;ms&quot;,&quot;size&quot;:400,&quot;sizes&quot;:[]}}\" data-widget_type=\"nested-accordion.default\">\n\t\t\t\t\t\t\t<div class=\"e-n-accordion\" aria-label=\"Accordion. Open links with Enter or Space, close with Escape, and navigate with Arrow Keys\">\n\t\t\t\t\t\t<details id=\"e-n-accordion-item-1010\" class=\"e-n-accordion-item\" >\n\t\t\t\t<summary class=\"e-n-accordion-item-title\" data-accordion-index=\"1\" tabindex=\"0\" aria-expanded=\"false\" aria-controls=\"e-n-accordion-item-1010\" >\n\t\t\t\t\t<span class='e-n-accordion-item-title-header'><div class=\"e-n-accordion-item-title-text\"> Why do most ANVISA medical device applications face delays in Brazil? <\/div><\/span>\n\t\t\t\t\t\t\t<span class='e-n-accordion-item-title-icon'>\n\t\t\t<span class='e-opened' ><svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-minus\" viewBox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M416 208H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h384c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\"><\/path><\/svg><\/span>\n\t\t\t<span class='e-closed'><svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-plus\" viewBox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M416 208H272V64c0-17.67-14.33-32-32-32h-32c-17.67 0-32 14.33-32 32v144H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h144v144c0 17.67 14.33 32 32 32h32c17.67 0 32-14.33 32-32V304h144c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\"><\/path><\/svg><\/span>\n\t\t<\/span>\n\n\t\t\t\t\t\t<\/summary>\n\t\t\t\t<div role=\"region\" aria-labelledby=\"e-n-accordion-item-1010\" class=\"elementor-element elementor-element-8c5dbd6 e-con-full e-flex e-con e-child\" data-id=\"8c5dbd6\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-c9ae8da elementor-widget elementor-widget-text-editor\" data-id=\"c9ae8da\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p>Most delays stem from incorrect risk classification under RDC 751\/2022, unlocalized Portuguese labeling\/IFUs, missing INMETRO certificates, and poor responses to official ANVISA queries (<em>Exig\u00eancias<\/em>).<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/details>\n\t\t\t\t\t\t<details id=\"e-n-accordion-item-1011\" class=\"e-n-accordion-item\" >\n\t\t\t\t<summary class=\"e-n-accordion-item-title\" data-accordion-index=\"2\" tabindex=\"-1\" aria-expanded=\"false\" aria-controls=\"e-n-accordion-item-1011\" >\n\t\t\t\t\t<span class='e-n-accordion-item-title-header'><div class=\"e-n-accordion-item-title-text\"> Can I use my US FDA 510(k) clearance or CE Mark to obtain ANVISA approval? <\/div><\/span>\n\t\t\t\t\t\t\t<span class='e-n-accordion-item-title-icon'>\n\t\t\t<span class='e-opened' ><svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-minus\" viewBox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M416 208H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h384c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\"><\/path><\/svg><\/span>\n\t\t\t<span class='e-closed'><svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-plus\" viewBox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M416 208H272V64c0-17.67-14.33-32-32-32h-32c-17.67 0-32 14.33-32 32v144H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h144v144c0 17.67 14.33 32 32 32h32c17.67 0 32-14.33 32-32V304h144c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\"><\/path><\/svg><\/span>\n\t\t<\/span>\n\n\t\t\t\t\t\t<\/summary>\n\t\t\t\t<div role=\"region\" aria-labelledby=\"e-n-accordion-item-1011\" class=\"elementor-element elementor-element-f117671 e-con-full e-flex e-con e-child\" data-id=\"f117671\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-2da4cca elementor-widget elementor-widget-text-editor\" data-id=\"2da4cca\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p>While FDA and CE technical data serve as supporting evidence, ANVISA does not grant automatic approval. Devices must independently satisfy Brazilian technical standards and B-GMP regulations.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/details>\n\t\t\t\t\t\t<details id=\"e-n-accordion-item-1012\" class=\"e-n-accordion-item\" >\n\t\t\t\t<summary class=\"e-n-accordion-item-title\" data-accordion-index=\"3\" tabindex=\"-1\" aria-expanded=\"false\" aria-controls=\"e-n-accordion-item-1012\" >\n\t\t\t\t\t<span class='e-n-accordion-item-title-header'><div class=\"e-n-accordion-item-title-text\"> What is an ANVISA Exig\u00eancia, and how long do I have to respond? <\/div><\/span>\n\t\t\t\t\t\t\t<span class='e-n-accordion-item-title-icon'>\n\t\t\t<span class='e-opened' ><svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-minus\" viewBox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M416 208H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h384c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\"><\/path><\/svg><\/span>\n\t\t\t<span class='e-closed'><svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-plus\" viewBox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M416 208H272V64c0-17.67-14.33-32-32-32h-32c-17.67 0-32 14.33-32 32v144H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h144v144c0 17.67 14.33 32 32 32h32c17.67 0 32-14.33 32-32V304h144c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\"><\/path><\/svg><\/span>\n\t\t<\/span>\n\n\t\t\t\t\t\t<\/summary>\n\t\t\t\t<div role=\"region\" aria-labelledby=\"e-n-accordion-item-1012\" class=\"elementor-element elementor-element-0e26460 e-con-full e-flex e-con e-child\" data-id=\"0e26460\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-467d104 elementor-widget elementor-widget-text-editor\" data-id=\"467d104\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p>An <em>Exig\u00eancia<\/em> is a formal technical query issued by ANVISA reviewers. Applicants are legally allotted 30 consecutive days to submit a complete response, extendable once by 30 days upon request.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/details>\n\t\t\t\t\t\t<details id=\"e-n-accordion-item-1013\" class=\"e-n-accordion-item\" >\n\t\t\t\t<summary class=\"e-n-accordion-item-title\" data-accordion-index=\"4\" tabindex=\"-1\" aria-expanded=\"false\" aria-controls=\"e-n-accordion-item-1013\" >\n\t\t\t\t\t<span class='e-n-accordion-item-title-header'><div class=\"e-n-accordion-item-title-text\"> Do all medical devices require a B-GMP certificate from ANVISA? <\/div><\/span>\n\t\t\t\t\t\t\t<span class='e-n-accordion-item-title-icon'>\n\t\t\t<span class='e-opened' ><svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-minus\" viewBox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M416 208H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h384c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\"><\/path><\/svg><\/span>\n\t\t\t<span class='e-closed'><svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-plus\" viewBox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M416 208H272V64c0-17.67-14.33-32-32-32h-32c-17.67 0-32 14.33-32 32v144H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h144v144c0 17.67 14.33 32 32 32h32c17.67 0 32-14.33 32-32V304h144c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\"><\/path><\/svg><\/span>\n\t\t<\/span>\n\n\t\t\t\t\t\t<\/summary>\n\t\t\t\t<div role=\"region\" aria-labelledby=\"e-n-accordion-item-1013\" class=\"elementor-element elementor-element-382ab37 e-con-full e-flex e-con e-child\" data-id=\"382ab37\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-12e80f9 elementor-widget elementor-widget-text-editor\" data-id=\"12e80f9\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p>No. B-GMP certification under RDC 665\/2022 is mandatory for Class III and Class IV devices. Class I and Class II devices must comply with B-GMP standards but do not require pre-market factory audits.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/details>\n\t\t\t\t\t\t<details id=\"e-n-accordion-item-1014\" class=\"e-n-accordion-item\" >\n\t\t\t\t<summary class=\"e-n-accordion-item-title\" data-accordion-index=\"5\" tabindex=\"-1\" aria-expanded=\"false\" aria-controls=\"e-n-accordion-item-1014\" >\n\t\t\t\t\t<span class='e-n-accordion-item-title-header'><div class=\"e-n-accordion-item-title-text\"> Can a foreign medical device manufacturer hold an ANVISA registration directly? <\/div><\/span>\n\t\t\t\t\t\t\t<span class='e-n-accordion-item-title-icon'>\n\t\t\t<span class='e-opened' ><svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-minus\" viewBox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M416 208H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h384c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\"><\/path><\/svg><\/span>\n\t\t\t<span class='e-closed'><svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-plus\" viewBox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M416 208H272V64c0-17.67-14.33-32-32-32h-32c-17.67 0-32 14.33-32 32v144H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h144v144c0 17.67 14.33 32 32 32h32c17.67 0 32-14.33 32-32V304h144c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\"><\/path><\/svg><\/span>\n\t\t<\/span>\n\n\t\t\t\t\t\t<\/summary>\n\t\t\t\t<div role=\"region\" aria-labelledby=\"e-n-accordion-item-1014\" class=\"elementor-element elementor-element-18f6137 e-con-full e-flex e-con e-child\" data-id=\"18f6137\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-f90a861 elementor-widget elementor-widget-text-editor\" data-id=\"f90a861\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p>No. Foreign manufacturers must appoint a licensed Brazilian Registration Holder (BRH)\u2014either an independent regulatory entity or a local distributor\u2014to legally hold the product registration in Brazil.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/details>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t<script type=\"application\/ld+json\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"Why do most ANVISA medical device applications face delays in Brazil?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Most delays stem from incorrect risk classification under RDC 751\\\/2022, unlocalized Portuguese labeling\\\/IFUs, missing INMETRO certificates, and poor responses to official ANVISA queries (Exig\\u00eancias).\"}},{\"@type\":\"Question\",\"name\":\"Can I use my US FDA 510(k) clearance or CE Mark to obtain ANVISA approval?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"While FDA and CE technical data serve as supporting evidence, ANVISA does not grant automatic approval. Devices must independently satisfy Brazilian technical standards and B-GMP regulations.\"}},{\"@type\":\"Question\",\"name\":\"What is an ANVISA Exig\\u00eancia, and how long do I have to respond?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"An Exig\\u00eancia is a formal technical query issued by ANVISA reviewers. Applicants are legally allotted 30 consecutive days to submit a complete response, extendable once by 30 days upon request.\"}},{\"@type\":\"Question\",\"name\":\"Do all medical devices require a B-GMP certificate from ANVISA?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"No. B-GMP certification under RDC 665\\\/2022 is mandatory for Class III and Class IV devices. Class I and Class II devices must comply with B-GMP standards but do not require pre-market factory audits.\"}},{\"@type\":\"Question\",\"name\":\"Can a foreign medical device manufacturer hold an ANVISA registration directly?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"No. Foreign manufacturers must appoint a licensed Brazilian Registration Holder (BRH)\\u2014either an independent regulatory entity or a local distributor\\u2014to legally hold the product registration in Brazil.\"}}]}<\/script>\n\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>Discover why ANVISA medical device approvals fail in Brazil and how to resolve classification errors, documentation gaps, labeling issues, regulatory queries, and submission delays.<\/p>\n","protected":false},"author":2,"featured_media":23216,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[170],"tags":[],"class_list":["post-20290","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-anvisa"],"_links":{"self":[{"href":"https:\/\/operonstrategist.com\/br-en\/wp-json\/wp\/v2\/posts\/20290","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/operonstrategist.com\/br-en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/operonstrategist.com\/br-en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/operonstrategist.com\/br-en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/operonstrategist.com\/br-en\/wp-json\/wp\/v2\/comments?post=20290"}],"version-history":[{"count":23,"href":"https:\/\/operonstrategist.com\/br-en\/wp-json\/wp\/v2\/posts\/20290\/revisions"}],"predecessor-version":[{"id":42633,"href":"https:\/\/operonstrategist.com\/br-en\/wp-json\/wp\/v2\/posts\/20290\/revisions\/42633"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/operonstrategist.com\/br-en\/wp-json\/wp\/v2\/media\/23216"}],"wp:attachment":[{"href":"https:\/\/operonstrategist.com\/br-en\/wp-json\/wp\/v2\/media?parent=20290"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/operonstrategist.com\/br-en\/wp-json\/wp\/v2\/categories?post=20290"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/operonstrategist.com\/br-en\/wp-json\/wp\/v2\/tags?post=20290"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}